Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Baby Eva Named After Pioneering IVF Test

June 14, 2013

First baby born in Scotland using new ground-breaking IVF technology

MENLO PARK, California, June 14, 2013 /PRNewswire/ –

Auxogyn announces the birth of the first baby in Scotland to be born using a
ground-breaking new approach to IVF, the ‘Early Embryo Viability Assessment’ (Eeva
[http://www.eevaivf.com ](TM)) test, that improves embryo selection.

Video [http://www.eevaivf.com/video-of-eeva-conception ] and photos available at 10am
BST

Scotland is welcoming Baby Eva today, the world’s first baby to be born and named by
her parents after the new Eeva test. Eva was born on 11th June following Susan
Walker-Dempster and David Dempster’s hardship of trying to build a family together. Susan
and David chose to have the Eeva test at the GCRM to increase their chances of IVF
success. The new mother, Susan said “we wanted every chance to be successful, so we chose
Eeva.”

The Eeva test uses unique predictive software in combination with a time-lapse
analysis technique to automatically analyse embryo development against scientifically and
clinically validated cell-division parameters. The test aids embryologists in selecting
the most viable embryos for transfer, potentially increasing the chances of a successful
IVF cycle.

“We are delighted to hear the news of this healthy birth and wish the family the very
best,” said Lissa Goldenstein, President and CEO of Auxogyn. “The Eeva test has been
developed to give IVF clinicians objective information about the embryo and provide
insight into its growth potential. With more couples choosing to use Eeva, we are looking
forward to many more births like Baby Eva today.”

Scientist Professor Richard Fleming at GCRM said: “We are very proud to be among the
first clinics in the world to announce this news as it demonstrates how successful this
new technology can be in enabling couples to have a higher chance of conceiving a baby
with IVF. GCRM has always strived to be one of the leading IVF Centres in Europe, offering
couples the latest innovations and best possible outcomes. The Eeva test is the practical
end point of good quality research and is the start of a new chapter in the evolution of
IVF.”

About IVF

Infertility affects one out of every 6 couples and about 7.3 million women and their
partners in the U.S..The demand for assisted reproduction tools and procedures is growing
worldwide. This growth is occurring despite the significant cost per IVF cycle and the low
success rate, with approximately one-third of cycles resulting in a live birth. This
necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading
to greater physical, emotional, practical and financial costs, before determining if
pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test

The Eeva test provides IVF clinicians with predictive information about the embryo’s
development potential to help improve embryo selection. Eeva’s proprietary software
automatically analyzes embryo development against scientifically and clinically validated
cell-division parameters conceived by researchers at Stanford University in the US. With
results from the Eeva test, IVF teams now have predictive and objective information to
combine morphological assessment to help improve the embryo selection decision. The Eeva
Test was validated in a prospective, multi-centre, 54-patient clinical trial with 758
embryos. Embryologists using Eeva were significantly able to improve their ability to
identify non-viable embryos relative to traditional methods alone. Additionally, Eeva was
able to increase the consistency of embryo assessment across embryologists. Results of
this study were presented in July 2012 at the European Society of Human Reproduction and
Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and
Sterility, May 2013.

Eeva is currently CE Marked and available for use in the EU and is pending FDA
clearance in the United States. For a full list of clinics offering the Eeva test
pleasevisithttp://www.eevaivf.com or follow us on Twitter @EevaIVF.

About Auxogyn

Auxogyn is revolutionising the field of reproductive medicine by translating
scientific discoveries in early embryo development into clinical tools. The Company’s
flagship product, the Eeva(TM) Test, delivers consistent, objective information regarding
embryo viability that IVF clinicians and patients can use to make important treatment
decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck
Serono Ventures, SR One and TPG Biotech. For more information visit
http://www.auxogyn.com and follow us on Twitter @Auxogyn.

Media contacts:

Sylvie Berrebi :sylvie@sciad.com +44-(0)-7795-197271.

SOURCE Auxogyn


Source: PR Newswire